Phase 1
- Breast, Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Phase I, Rectum, Stomach, ThyroidA Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
- Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Urinary, Pancreas, Phase I, Urinary BladderA Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors
- Colon, Esophagus, Liver, Lung, Other Digestive Organ, Phase I, StomachA Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors
- Colon, Liver, Lung, Other Skin, Other Urinary, Phase I, Rectum, Urinary BladderA Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors